First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. (nature.com)

Authors: Shitara K … Klempner SJ Journal: Nature Medicine Published: 2026-06-01 DOI: https://doi.org/10.1038/s41591-026-04306-9